Forcyte Biotechnologies, Inc. is the first company aiming to tackle diseases of cell mechanobiology by directly screening contractile cell force in an automation-friendly & high-throughput format.

Market:

Forcyte Biotechnologies, Inc. provides predictive disease models and screening technology for disease of cellular mechanobiology and mechanical force generation, which collectively represent hundreds of millions of dollars in annual preclinical R&D expenditures, and billions more in economic burden.

Technology:

Forcyte combines advances in microtechnology and automation to unlock access to cellular force generation as a quantitative metric in high-throughput screening and analysis. We build and deploy assays with direct links to functional pathophysiology that can be utilized by anyone with minimal training to obtain high-quality and functional data on cellular contraction, at the single-cell or multi- cellular levels.

Advantages:

  • Automation-friendly (25/96/384-wellplate formats)
  • Highly-parallelized (evaluates 100,000s of cells)
  • Quantitative readout for cellular force generation
  • Single-cell resolution
  • No special expertise needed

Development Stage:

  • Prototype

Patents Pending:

  • Device and method for force phenotyping of cells for high-throughput screening
    and analysis; PCT US20170176415A1  -granted on 9/25/18

Select Publications:

Contact:

Email: Ivan Pushkarsky, ivan@forcytebio.com
Phone: 859-420-4398
Website: forcytebio.com
LinkedIn

Portfolio Companies